Market capitalization | $466.75m |
Enterprise Value | $-140.59m |
P/E (TTM) P/E ratio | 47.64 |
EV/FCF (TTM) EV/FCF | 0.76 |
EV/Sales (TTM) EV/Sales | -0.83 |
P/S ratio (TTM) P/S ratio | 2.77 |
P/B ratio (TTM) P/B ratio | 0.78 |
Revenue growth (TTM) Revenue growth | 188.64% |
Revenue (TTM) Revenue | $168.59m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
7 Analysts have issued a Immatics N.V forecast:
7 Analysts have issued a Immatics N.V forecast:
Dec '24 |
+/-
%
|
||
Revenue | 169 169 |
189%
189%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -29 -29 |
72%
72%
|
EBIT (Operating Income) EBIT | -42 -42 |
62%
62%
|
Net Profit | 16 16 |
115%
115%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Head office | Netherlands |
CEO | Harpreet Singh-Jasuja |
Employees | 423 |
Founded | 2020 |
Website | www.immatics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.